{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:27:44Z","timestamp":1754152064865,"version":"3.41.2"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,21]]},"DOI":"10.7759\/cureus.88424","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T12:52:43Z","timestamp":1753102363000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Dulaglutide for Weight Reduction Among Diabetic Patients in Saudi Arabia: A Retrospective Cohort Study"],"prefix":"10.7759","author":[{"given":"Gadah K","family":"Alonazi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lamia A","family":"Alawuad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Obesity","author":"Panuganti KK","year":"2025","unstructured":"Panuganti KK, Nguyen M, Kshirsagar RK. Obesity. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2025."},{"unstructured":"Obesity and overweight. (2024). Accessed. July 10, 2025: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight.","key":"ref2"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2017.03.107","article-title":"Morbidity and mortality associated with obesity","volume":"5","author":"Abdelaal M","year":"2017","unstructured":"Abdelaal M, le Roux CW, Docherty NG. Morbidity and mortality associated with obesity. Ann Transl Med. 2017, 5:10.21037\/atm.2017.03.107","journal-title":"Ann Transl Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2008.102","article-title":"Global burden of obesity in 2005 and projections to 2030","volume":"32","author":"Kelly T","year":"2008","unstructured":"Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond). 2008, 32:1431-7. 10.1038\/ijo.2008.102","journal-title":"Int J Obes (Lond)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare9030311","article-title":"Obesity in Saudi Arabia in 2020: prevalence, distribution, and its current association with various health conditions","volume":"9","author":"Althumiri NA","year":"2021","unstructured":"Althumiri NA, Basyouni MH, AlMousa N, et al.. Obesity in Saudi Arabia in 2020: prevalence, distribution, and its current association with various health conditions. Healthcare (Basel). 2021, 9:10.3390\/healthcare9030311","journal-title":"Healthcare (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley TM","year":"2021","unstructured":"Powell-Wiley TM, Poirier P, Burke LE, et al.. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021, 143:984-1010. 10.1161\/CIR.0000000000000973","journal-title":"Circulation"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/cells10040933","article-title":"Obesity as a risk factor for severe COVID-19 and complications: a review","volume":"10","author":"Demeulemeester F","year":"2021","unstructured":"Demeulemeester F, de Punder K, van Heijningen M, van Doesburg F. Obesity as a risk factor for severe COVID-19 and complications: a review. Cells. 2021, 10:10.3390\/cells10040933","journal-title":"Cells"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000442721","article-title":"European Guidelines for Obesity Management in Adults","volume":"8","author":"Yumuk V","year":"2015","unstructured":"Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, Toplak H. European Guidelines for Obesity Management in Adults. Obes Facts. 2015, 8:402-24. 10.1159\/000442721","journal-title":"Obes Facts"},{"key":"ref9","article-title":"Glucagon-like peptide-1 receptor agonists","author":"Collins L","year":"2025","unstructured":"Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2025."},{"unstructured":"Glucagon-like peptide-1 (GLP-1) agonist - incretin mimetics. Accessed. July 10, 2025: https:\/\/globalrph.com\/drugs\/diabetes-incretin-mimetics\/.","key":"ref10"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis","volume":"19","author":"Htike ZZ","year":"2017","unstructured":"Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017, 19:524-36. 10.1111\/dom.12849","journal-title":"Diabetes Obes Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-0241","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials","volume":"48","author":"Lee MM","year":"2025","unstructured":"Lee MM, Sattar N, Pop-Busui R, et al.. Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials. Diabetes Care. 2025, 48:846-57. 10.2337\/dc25-0241","journal-title":"Diabetes Care"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12119","article-title":"The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications","volume":"16","author":"Madsbad S","year":"2014","unstructured":"Madsbad S. The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. Diabetes Obes Metab. 2014, 16:9-21. 10.1111\/dom.12119","journal-title":"Diabetes Obes Metab"},{"key":"ref15","article-title":"Trulicity (dulaglutide): a new GLP-1 receptor agonist once-weekly subcutaneous injection approved for the treatment of patients with type 2 diabetes","volume":"8","author":"Fala L","year":"2015","unstructured":"Fala L. Trulicity (dulaglutide): a new GLP-1 receptor agonist once-weekly subcutaneous injection approved for the treatment of patients with type 2 diabetes. Am Health Drug Benefits. 2015, 8:131-4.","journal-title":"Am Health Drug Benefits"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12710","article-title":"Dose-response relationship between statin therapy and glycaemia in community-based patients with type 2 diabetes: the Fremantle Diabetes Study","volume":"18","author":"Davis TM","year":"2016","unstructured":"Davis TM, Badshah I, Chubb SA, Davis WA. Dose-response relationship between statin therapy and glycaemia in community-based patients with type 2 diabetes: the Fremantle Diabetes Study. Diabetes Obes Metab. 2016, 18:1143-6. 10.1111\/dom.12710","journal-title":"Diabetes Obes Metab"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker DJ","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018, 27:740-56. 10.1016\/j.cmet.2018.03.001","journal-title":"Cell Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2810","article-title":"Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program","volume":"32","author":"Jendle J","year":"2016","unstructured":"Jendle J, Grunberger G, Blevins T, Giorgino F, Hietpas RT, Botros FT. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev. 2016, 32:776-90. 10.1002\/dmrr.2810","journal-title":"Diabetes Metab Res Rev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein HC","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al.. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019, 394:131-8. 10.1016\/S0140-6736(19)31150-X","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"crossref","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos TD","year":"2014","unstructured":"Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014, 11:202-30.","journal-title":"Rev Diabet Stud"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S001","article-title":"Improving care and promoting health in populations: standards of care in diabetes - 2023","volume":"46","author":"ElSayed NA","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, et al.. Improving care and promoting health in populations: standards of care in diabetes - 2023. Diabetes Care. 2023, 46:10-8. 10.2337\/dc23-S001","journal-title":"Diabetes Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/374086-efficacy-and-safety-of-dulaglutide-for-weight-reduction-among-diabetic-patients-in-saudi-arabia-a-retrospective-cohort-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T12:52:44Z","timestamp":1753102364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/374086-efficacy-and-safety-of-dulaglutide-for-weight-reduction-among-diabetic-patients-in-saudi-arabia-a-retrospective-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.88424","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,21]]}}}